SCV
ABOS icon

Sands Capital Ventures’s Acumen Pharmaceuticals ABOS Stock Holding History

Sands Capital Ventures’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.93M Hold
3,720,105
– – 1.62% 15
2026
Q1 		$8.78M Buy
3,720,105
+303,030
+9% +$773K 2.08% 12
2025
Q4 		$7.21M Hold
3,417,075
– – 1.39% 14
2025
Q3 		$5.84M Hold
3,417,075
– – 1.28% 13
2025
Q2 		$3.96M Hold
3,417,075
– – 0.78% 15
2025
Q1 		$3.76M Hold
3,417,075
– – 0.92% 17
2024
Q4 		$5.88M Hold
3,417,075
– – 1.28% 15
2024
Q3 		$8.47M Hold
3,417,075
– – 2.38% 9
2024
Q2 		$8.27M Hold
3,417,075
– – 2.77% 8
2024
Q1 		$13.8M Hold
3,417,075
– – 3.34% 7
2023
Q4 		$13.1M Hold
3,417,075
– – 3.65% 7
2023
Q3 		$14.2M Hold
3,417,075
– – 4.2% 10
2023
Q2 		$16.4M Hold
3,417,075
– – 4.86% 8
2023
Q1 		$13.9M Hold
3,417,075
– – 3.43% 10
2022
Q4 		$18.5M Hold
3,417,075
– – 5.05% 8
2022
Q3 		$34.3M Hold
3,417,075
– – 9.96% 5
2022
Q2 		$16.1M Hold
3,417,075
– – 4.41% 10
2022
Q1 		$13.4M Hold
3,417,075
– – 2.79% 9
2021
Q4 		$23.1M Hold
3,417,075
– – 3.42% 8
2021
Q3 		$50.8M Buy
+3,417,075
New +$56.9M 7.66% 5

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $34.3B AUM 27.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Sands Capital Ventures's ABOS Position: Q2 2026 in Review

Sands Capital Ventures held its Acumen Pharmaceuticals (ABOS) position steady in Q2 2026 at 3,720,105 shares worth $9.93M. The position accounts for 1.62% of the portfolio, ranked #15.

Sands Capital Ventures first reported a position in ABOS in Q3 2021 and has held it in 20 quarters since. The position peaked at $50.8M in Q3 2021. 91 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Sands Capital Ventures held 3,720,105 shares of Acumen Pharmaceuticals worth $9.93M as of Q2 2026.
  • Sands Capital Ventures left its Acumen Pharmaceuticals share count unchanged in Q2 2026.
  • Acumen Pharmaceuticals made up 1.62% of Sands Capital Ventures's portfolio in Q2 2026, its #15 holding.
  • Sands Capital Ventures first reported a position in Acumen Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Sands Capital Ventures's Acumen Pharmaceuticals position peaked at $50.8M in Q3 2021.
  • 91 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Sands Capital Ventures's 13F filing for Q2 2026, filed 13 Aug 2026.